HSBC Maintains Buy on Repligen, Lowers Price Target to $150

Benzinga Newsdesk www.benzinga.com Negative 75.6%

Neg 75.6% Neu 0% Pos 0%

HSBC analyst Sidharth Sahoo maintains Repligen (NASDAQ:RGEN) with a Buy and lowers the price target from $170 to $150.

Comments

No comments yet. Be the first!